

■ General Information

Applications

- Immunohistochemistry
 - TUNEL for apoptosis
- In situ hybridization (ISH)
 - mRNA
 - miRNA
 - Fluorescent In situ hybridization (FISH)

Storage and stability

- Individual slide is put in an air-tight pack with inert gas.
- If the slides are stored at 4C, they are good for up to one year.

How processed

- Tissues were initially fixed with formalin except for some of the animal tissues
- Then, dehydrated with gradient ethanol; typically 1 hour each progressive steps; 70%, 90%, 95%, 99%, 100% x 3 times.
- Cleared by xylene, three changes for 1 hour each.
- Infiltrated with 60°C paraffin, three changes for 1 hour each
- Sectioned by microtome in 4 µm thickness

Before use

- Dry slides for 1 hour in a oven at 60C.
- Dewax slides in xylene for 4 minutes x 5 times.
- Hydrate slides in 100%, 95% and 75% ethanol for 3 minutes x 2 times each.
- Immerse slides in tap water for 5 minutes.

Slide orientation

- In most of the slides with 59 or 60 cores, the orientation is as below unless indicated otherwise. #60 location is usually filled with carbon for orientation.

Shaded area	1	2	3	4	5	6	7	8	9	10	
	11	12	13	14	15	16	17	18	19	20	
	21	22	23	24	25	26	27	28	29	30	
	30	32	33	34	35	36	37	38	39	40	
	41	42	43	44	45	46	47	48	49	50	
	51	52	53	54	55	56	57	58	59	60	

■ Tissue types*

The "tissue type" column in the data sheet denotes the following categories.

1. normal tissue from a non-cancer patient
2. normal tissue from a cancer patient, but the cancer involves unrelated organ
3. normal tissue adjacent to the cancer
4. benign tumor
5. tumor of borderline malignancy or uncertain malignant potential
6. cancer

NBP2-30331 - Human Various Tissue MicroArray (Cancer)

No.	Age	Sex	Organ	Diagnosis	pTNM	Stage	Tissue type*
301	50	F	Ovary	adenocarcinoma, serous	T3N1MO	III C	6
302	70	F	Ovary	adenocarcinoma, serous	T2N0MO	II	6
303	43	F	Ovary	adenocarcinoma, serous	T3cN0MO	III C	6
304	51	F	Ovary	adenocarcinoma, serous	T2N1MO	III C	6
305	57	F	Ovary	adenocarcinoma, serous	T3bN1MO	III C	6
306	64	F	Ovary	adenocarcinoma, serous	T3cN1MO	III C	6
307	57	F	Ovary	adenocarcinoma, serous	T3cN1MO	III C	6
308	45	F	Ovary	adenocarcinoma, serous	T1bN0MO	I B	6
309	65	F	Ovary	adenocarcinoma, serous	T3cN0MO	III C	6
310	55	F	Ovary	adenocarcinoma, serous	T3bN0MO	III B	6
311	41	F	Ovary	adenocarcinoma, serous	T2cN1MO	III C	6
312	34	F	Ovary	small cell carcinoma	T1aN0MO	I A	6
313	68	F	Ovary	undifferentiated carcinoma	T1bN0MO	I B	6
314	57	F	Ovary	adenocarcinoma, serous, metastasis to colon	M1	IV	6
315	65	F	Ovary	adenocarcinoma, poorly differentiated, metastasis to omentum	M1	IV	6
316	70	F	Ovary	malignant Mullerian mixed tumor	T1bN0MO	I B	6
317	56	F	Ovary	malignant Mullerian mixed tumor	T1bN0MO	I B	6
318	38	F	Ovary	mixed Brenner tumor and mucinous adenoma	T1aN0MO	I A	4
319	34	F	Ovary	granulosa cell tumor	T1aN0MO	I A	5
320	44	F	Ovary	granulosa cell tumor	T1aN0MO	I A	5
321	54	F	Ovary	Sertoli-Leydig cell tumor	T1bN0MO	I B	5
322	24	F	Ovary	Sertoli-Leydig cell tumor	T1aN0MO	I A	5
323	34	F	Ovary	dysgerminoma	T1aN0MO	I A	6
324	23	F	Ovary	dysgerminoma	T1aN0MO	I A	6
325	23	F	Ovary	dysgerminoma	T1aN0MO	I A	6
326	21	F	Ovary	dysgerminoma	T1aN0MO	I A	6
327	23	F	Ovary	endodermal sinus tumor	T3cN0MO	III C	6
328	57	F	Myometrium	leiomyosarcoma, metastasis to pelvic cavity	T2aN0MO	II A	6
329	39	F	Myometrium	malignant Mullerian mixed tumor, metastasis to pelvic cavity	T3aN0MO	III A	6
330	75	M	Prostate	adenocarcinoma, grade 6/10	T1bN0MO	II	6
331	70	M	Prostate	adenocarcinoma, grade 7/10	T1N0MO	II	6
332	64	M	Prostate	adenocarcinoma, grade 7/10	T4N0MO	IV	6
333	68	M	Prostate	adenocarcinoma, grade 9/10	T1N0MO	II	6
334	51	M	Prostate	adenocarcinoma, grade 10/10	T1N0MO	II	6
335	50	M	Prostate	transitional cell carcinoma, grae 3/3	T4N0MO	IV	6
336	34	M	Testis	seminoma, classic	T1N0MO	I	6
337	26	M	Testis	seminoma, classic	T1N0MO	I	6
338	27	M	Testis	seminoma, classic	T3N0MO	I B	6
339	34	M	Testis	seminoma, classic	T3N0MO	I B	6
340	51	M	Testis	seminoma, classic	T4N0MO	I B	6
341	30	M	Testis	seminoma, classic	T1N0MO	I	6
342	33	M	Testis	seminoma, classic	T1N0MO	I	6
343	34	M	Testis	seminoma, anaplastic	T1N0MO	I	6
344	34	M	Testis	mixed germ cell tumor (seminoma predominant)	T1N0MO	I	6
345	.	Carbon			.	.	.
346	21	M	Testis	endodermal sinus tumor	T2N0MO	I B	6
347	24	M	Testis	endodermal sinus tumor, recurrent	T1N0MO	I A	6
348	21	M	Mediastinum	endodermal sinus tumor	.	.	6
349	81	M	Penile shaft	squamous cell carcinoma, poorly differentiated	.	.	6
350	43	M	Urinary bladder	adenocarcinoma, mucinous, urachal origin	T2aN0MO	II	6
351	70	F	Urinary bladder	transitional cell carcinoma, grade II	T1N0MO	I	6
352	67	M	Urinary bladder	transitional cell carcinoma, grade III	T1N0MO	I	6
353	59	M	Urinary bladder	transitional cell carcinoma, grade III	T3aN0MO	III	6
354	36	M	Urinary bladder	transitional cell carcinoma, grade III	T2aN0MO	II	6
355	47	M	Urinary bladder	transitional cell carcinoma, grade III	T2aN0MO	II	6
356	52	M	Urinary bladder	transitional cell carcinoma, grade III	T3aN0MO	III	6
357	60	M	Urinary bladder	transitional cell carcinoma, grade III	T3bN1MO	IV	6
358	65	M	Urinary bladder	transitional cell carcinoma, grade III	T4aN2MO	IV	6
359	52	F	Urinary bladder	transitional cell carcinoma, grade III	T2aN0MO	II	6
360	76	M	Urinary bladder	transitional cell carcinoma, grade III	T2aN0MO	II	6
361	74	M	Urinary bladder	transitional cell carcinoma, grade III	T1N0MO	I	6
362	58	M	Urinary bladder	transitional cell carcinoma, grade III	T3N0MO	III	6
363	76	M	Urinary bladder	transitional cell carcinoma, grade III	T3N0MO	III	6
364	63	M	Urinary bladder	transitional cell carcinoma, grade III	T3bN0MO	III	6
365	56	M	Kidney, pelvis	transitional cell carcinoma, grade I	T1N0MO	I	6
366	43	M	Kidney, pelvis	transitional cell carcinoma, grade II	T1N0MO	I	6
367	53	M	Kidney	renal cell carcinoma, clear cell type	T1bN0MO	I	6
368	59	M	Kidney	renal cell carcinoma, clear cell type	T2N0MO	II	6
369	40	M	Kidney	renal cell carcinoma, clear cell type	T1aN0MO	I	6
370	44	F	Kidney	renal cell carcinoma, clear cell type	T2N0MO	II	6
371	63	M	Kidney	renal cell carcinoma, clear cell type	T3N0MO	III	6
372	62	F	Kidney	renal cell carcinoma, clear cell type	T3N0MO	III	6
373	28	F	Kidney	renal cell carcinoma, clear cell type	T1bN0MO	I	6
374	35	M	Kidney	renal cell carcinoma, clear cell type	T1aN0MO	I	6
375	48	M	Kidney	renal cell carcinoma, clear cell type	T1bN0MO	I	6
376	48	M	Kidney	renal cell carcinoma, chromophobe type	T1aN0MO	I	6
377	36	M	Kidney	renal cell carcinoma, sarcomatoid type	M1	IV	6
378	68	M	Kidney	renal cell carcinoma, sarcomatoid type	M1	IV	6
379	76	M	Kidney	renal cell carcinoma, sarcomatoid type	T3N0MO	III	6
380	27	F	Kidney	embryonal sarcoma	T3N0MO	III	6

No.	Age	Sex	Organ	Diagnosis	TNM	Stage	Tissue type*
381	60	F	Brain, meninx	meningioma, transitional	.	.	4
382	60	M	Brain, meninx	meningioma, meningotheliomatous	.	.	4
383	42	F	Brain, meninx	meningioma, meningotheliomatous	.	.	4
384	38	M	Brain, meninx	meningioma, atypical	.	.	5
385	62	M	Brain	glioblastoma	.	.	6
386	46	M	Brain, frontal lobe	oligodendrogloma, grade II	.	.	6
387	60	F	Thyroid	papillary carcinoma	T4aNOMO	IVA	6
388	43	F	Thyroid	papillary carcinoma	T4aNOMO	IVA	6
389	63	F	Thyroid	papillary carcinoma	T4aN1MO	IVA	6
390	27	M	Thyroid	papillary carcinoma	T4aN1MO	IVA	6
391	32	F	Thyroid	papillary carcinoma	T2N1aMO	III	6
392	58	F	Thyroid	follicular carcinoma, minimally invasive	T2NOMO	II	6
393	17	M	Thyroid	medullary carcinoma	T2NOMO	II	6
394	28	F	Thyroid	papillary carcinoma, metastasis to lymph node	M1	IVC	6
395	.	.	Carbon
396	43	F	Thyroid	papillary carcinoma, metastasis to lymph node	N1b	.	6
397	70	F	Thyroid	papillary carcinoma, metastasis to lymph node	N1b	.	6
398	42	F	Thyroid	papillary carcinoma, metastasis to lymph node	N1b	.	6
399	24	M	Thyroid	papillary carcinoma, metastasis to lymph node	N1b	.	6
400	24	M	Thyroid	papillary carcinoma, metastasis to lymph node	N1b	.	6
401	61	F	Thyroid	papillary carcinoma, metastasis to lymph node	T4aN1bM0	IVA	6
402	33	F	Thyroid	follicular carcinoma, metastasis to mediastinum	M1	IVC	6
403	68	M	Adrenal gland	cortical carcinoma	.	.	6
404	18	F	Adrenal gland	cortical carcinoma	.	.	6
405	53	M	Adrenal gland	cortical carcinoma	.	.	6
406	18	F	Adrenal gland	cortical carcinoma	.	.	6
407	49	F	Adrenal gland	cortical carcinoma	.	.	6
408	64	F	Adrenal gland	cortical carcinoma	.	.	6
409	45	F	Adrenal gland	cortical carcinoma	.	.	6
410	41	F	Adrenal gland	cortical carcinoma	.	.	6
411	29	M	Adrenal gland	cortical carcinoma	.	.	6
412	31	F	Adrenal gland	cortical carcinoma	.	.	6
413	58	M	Adrenal gland	cortical carcinoma, recurrent	.	.	6
414	60	M	Adrenal gland	cortical carcinoma, recurrent	.	.	6
415	42	F	Adrenal gland	ganglioneuroblastoma	.	.	6
416	50	M	Adrenal gland	ganglioneuroma	.	.	4
417	64	F	Adrenal gland	pheochromocytoma	.	.	4
418	66	M	Adrenal gland	pheochromocytoma	.	.	4
419	20	M	Adrenal gland	pheochromocytoma	.	.	4
420	63	M	Adrenal gland	pheochromocytoma	.	.	4
421	47	F	Adrenal gland	pheochromocytoma	.	.	4
422	56	F	Adrenal gland	cortical carcinoma, metastasis to liver	.	.	6
423	59	F	Adrenal gland	cortical carcinoma, metastasis to liver	.	.	6
424	41	M	Thymus	thymic carcinoma	.	.	6
425	47	M	Thymus	thymoma, epithelial	.	.	5
426	37	M	Endocrine pancreas	islet cell tumor	.	.	6
427	62	M	Endocrine pancreas	islet cell tumor	.	.	6
428	58	F	Endocrine pancreas	islet cell tumor	.	.	6
429	53	F	Endocrine pancreas	islet cell carcinoma	.	.	6
430	61	M	Parotid gland	malignant lymphoma, follicular	.	.	6
431	60	F	Stomach	malignant lymphoma, MALToma	.	.	6
432	20	F	Small intestine	malignant lymphoma, diffuse large B cell	.	.	6
433	64	M	Stomach	malignant lymphoma, diffuse large B cell	.	.	6
434	43	M	Cecum	malignant lymphoma, diffuse large B cell	.	.	6
435	49	F	Duodenum	malignant lymphoma	.	.	6
436	33	F	Kidney	malignant lymphoma	.	.	6
437	46	M	Stomach	malignant lymphoma	.	.	6
438	53	M	Femur	malignant lymphoma	.	.	6
439	84	M	Jejunum	malignant lymphoma	.	.	6
440	43	M	Ileum & cecum	malignant lymphoma	.	.	6
441	51	M	Testis	malignant lymphoma, diffuse large B cell	.	.	6
442	51	M	Testis	malignant lymphoma, immunoblastic B cell	.	.	6
443	48	F	Ovary	malignant lymphoma	.	.	6
444	69	M	Common bile duct	malignant lymphoma	.	.	6
445	.	.	Carbon
446	49	M	Stomach	malignant lymphoma, diffuse large B cell	.	.	6
447	26	M	Lymph node	malignant lymphoma, diffuse large B cell	.	.	6
448	63	M	Retropertitoneum	malignant lymphoma	.	.	6
449	48	F	Uterus	granulocytic sarcoma	.	.	6
450	.	.	Carbon

TNM and Stage: AJCC Cancer Staging Manual (6th Edition)

